Mixed Analyst Opinions on AstraZeneca Ahead of Second-Quarter Results
Analysts at UBS and Berenberg maintain a positive stance on AstraZeneca, while HSBC and Deutsche Bank downgraded its stock due to concerns over trial outcomes. AstraZeneca's stock slipped on the Stockholm Stock Exchange as the OMXS30 index fell 0.4 percent.
AZN is facing a mixed bag of analyst opinions ahead of its second-quarter results, due July 27, 2026. UBS and Berenberg have reaffirmed their buy ratings for the company, indicating confidence in its longer-term outlook.
However, the picture is different at HSBC, which downgraded AstraZeneca's stock to a 'hold' rating after the Wainua (eplontersen) heart-disease trial failed to meet its primary endpoint, a setback that sent shares down sharply earlier in the week. Deutsche Bank has also reaffirmed its sell rating for the company.
These mixed signals show up in AstraZeneca's trading on the Stockholm exchange, where shares have also slipped alongside a softer OMXS30 index.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis